Literature DB >> 21099434

Hepatic encephalopathy: from pathophysiology to therapeutic management.

Michael Bismuth1, Natalie Funakoshi, Jean-François Cadranel, Pierre Blanc.   

Abstract

Hepatic encephalopathy is a complex and potentially reversible neuropsychiatric syndrome complicating acute or chronic liver disease. Clinical manifestations are multiple and varied, ranging from minimal neurological changes to coma. Ammonia is the main toxic substance involved in the pathogenesis of hepatic encephalopathy, although other mechanisms, such as modifications of the blood-brain barrier, disruptions in neurotransmission and abnormalities in GABAergic and benzodiazepine pathways may also play a role. The identification and treatment of precipitating factors is crucial in the management of patients with hepatic encephalopathy. Current treatments are based on reducing intestinal ammonia load by agents such as antibiotics or disaccharides, although their efficacy is yet to be clearly established.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21099434     DOI: 10.1097/MEG.0b013e3283417567

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  21 in total

Review 1.  Zinc and liver disease.

Authors:  Mohammad K Mohammad; Mohammad K Mohommad; Zhanxiang Zhou; Matthew Cave; Ashutosh Barve; Craig J McClain
Journal:  Nutr Clin Pract       Date:  2012-02       Impact factor: 3.080

2.  Clinical utility of breath ammonia for evaluation of ammonia physiology in healthy and cirrhotic adults.

Authors:  Lisa A Spacek; Matthew Mudalel; Frank Tittel; Terence H Risby; Steven F Solga
Journal:  J Breath Res       Date:  2015-12-14       Impact factor: 3.262

Review 3.  Management of overt hepatic encephalopathy.

Authors:  Praveen Sharma; Barjesh C Sharma
Journal:  J Clin Exp Hepatol       Date:  2014-05-10

Review 4.  Sleep, immunity and inflammation in gastrointestinal disorders.

Authors:  Tauseef Ali; James Choe; Ahmed Awab; Theodore L Wagener; William C Orr
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

5.  Decreased astrocytic thrombospondin-1 secretion after chronic ammonia treatment reduces the level of synaptic proteins: in vitro and in vivo studies.

Authors:  Arumugam R Jayakumar; Xiao Y Tong; Kevin M Curtis; Roberto Ruiz-Cordero; Nagarajarao Shamaladevi; Missa Abuzamel; Joshua Johnstone; Gabriel Gaidosh; Kakulavarapu V Rama Rao; Michael D Norenberg
Journal:  J Neurochem       Date:  2014-08-01       Impact factor: 5.372

6.  Benzodiazepine-associated hepatic encephalopathy significantly increased healthcare utilization and medical costs of Chinese cirrhotic patients: 7-year experience.

Authors:  Pei-Chang Lee; Ying-Ying Yang; Ming-Wei Lin; Ming-Chih Hou; Chien-Sheng Huang; Kuei-Chuan Lee; Ying-Wen Wang; Yun-Cheng Hsieh; Yi-Hsiang Huang; Chi-Jen Chu; Han-Chieh Lin
Journal:  Dig Dis Sci       Date:  2014-01-31       Impact factor: 3.199

Review 7.  Probiotics for people with hepatic encephalopathy.

Authors:  Rohan Dalal; Richard G McGee; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

Review 8.  Disaccharides in the treatment of hepatic encephalopathy.

Authors:  Praveen Sharma; Barjesh Chander Sharma
Journal:  Metab Brain Dis       Date:  2013-03-02       Impact factor: 3.584

Review 9.  The Current Hepatic Encephalopathy Pipeline.

Authors:  Alexander J Ryu; Robert S Rahimi; Michael D Leise
Journal:  J Clin Exp Hepatol       Date:  2020-01-14

10.  Cognitive functions in patients with liver cirrhosis: a tendency to commit more memory errors.

Authors:  Irena Ciećko-Michalska; Jan Wójcik; Magdalena Senderecka; Mirosław Wyczesany; Marek Binder; Jakub Szewczyk; Tomasz Dziedzic; Agnieszka Słowik; Tomasz Mach
Journal:  Med Sci Monit       Date:  2013-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.